This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Medical Device Stocks With Potential to Fight Recession Risk
by Indrajit Bandyopadhyay
The decline in U.S. GDP during the first quarter and 26% decline in the S&P 500 Index so far this year fuel the risk of a recession. MCK, PDCO & AMN have the potential to help investors ward off volatility risks going forward.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $122.77, marking a +1.37% move from the previous day.
Here's Why You Should Retain Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.
NextGen (NXGN)-InstaMed Ink Deal to Improve Payment Processing
by Zacks Equity Research
NextGen's (NXGN) latest expanded deal with InstaMed is expected to significantly simplify payment methods for both patients and providers.
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care.
Here's Why Momentum in AMN Healthcare (AMN) Should Keep going
by Zacks Equity Research
AMN Healthcare (AMN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
The Zacks Analyst Blog Highlights AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale
by Zacks Equity Research
AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale have been included in this Analyst Blog.
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Alcon's (ALC) Product Launches, Market Recovery Aid Growth
by Zacks Equity Research
Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.
Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
Here's Why Investors Should Retain Phibro (PAHC) For Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) major animal health products and robust vaccine sales.
LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis
by Zacks Equity Research
LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.
Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Fresenius (FMS) Faces Fraud Accusation From US Government
by Zacks Equity Research
The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.
Zacks.com featured highlights include AMN Healthcare Services, Otter Tail, Encore Capital Group and Cboe Global Markets
by Zacks Equity Research
AMN Healthcare Services, Otter Tail, Encore Capital Group and Cboe Global Markets are part of zacks Screen of the week article.
This Medical Supplier Is Pushing All-Time Highs
by Derek Lewis
McKesson shares have been scorching-hot year-to-date, increasing by more than 30% in value and extensively outperforming both its Zacks Sector and the S&P 500.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $110.24, moving -1.09% from the previous trading session.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) strong end market growth and noteworthy acquisitions.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
CVS Health (CVS) Pharmacy Claims Volume Grows, Margin Woes Stay
by Zacks Equity Research
CVS Health's (CVS) investments in constructing affordable housing units in Denver, Fresno, Nashville and San Antonio seem encouraging.
AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.
Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises
by Zacks Equity Research
Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).